OBJECTIVE: To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2-dose SARS-CoV-2 messenger RNA (mRNA) vaccination. METHODS: RMD patients (n = 1,377) who received 2-dose SARS-CoV-2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose (dose 1 and dose 2), and 1 month after dose 2, detailing any flares of RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression. RESULTS: Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS-CoV-2 infection (incidence rate ratio [IRR] 2.09, P = 0.02), flares in the 6 months preceding vaccination (IRR 2.36, P < 0.001), and the use of combination immunomodulatory therapy (IRR 1.95, P < 0.001). The most frequently reported local and systemic reactions included injection site pain (87% after dose 1, 86% after dose 2) and fatigue (60% after dose 1, 80% after dose 2). Reactogenicity increased after dose 2, particularly for systemic reactions. No allergic reactions or SARS-CoV-2 diagnoses were reported. CONCLUSION: Flares of underlying RMD following SARS-CoV-2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.
OBJECTIVE: To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2-dose SARS-CoV-2 messenger RNA (mRNA) vaccination. METHODS: RMD patients (n = 1,377) who received 2-dose SARS-CoV-2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose (dose 1 and dose 2), and 1 month after dose 2, detailing any flares of RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression. RESULTS: Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS-CoV-2 infection (incidence rate ratio [IRR] 2.09, P = 0.02), flares in the 6 months preceding vaccination (IRR 2.36, P < 0.001), and the use of combination immunomodulatory therapy (IRR 1.95, P < 0.001). The most frequently reported local and systemic reactions included injection site pain (87% after dose 1, 86% after dose 2) and fatigue (60% after dose 1, 80% after dose 2). Reactogenicity increased after dose 2, particularly for systemic reactions. No allergic reactions or SARS-CoV-2 diagnoses were reported. CONCLUSION: Flares of underlying RMD following SARS-CoV-2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Caoilfhionn M Connolly; Jake A Ruddy; Brian J Boyarsky; Robin K Avery; William A Werbel; Dorry L Segev; Jacqueline Garonzik-Wang; Julie J Paik Journal: Ann Rheum Dis Date: 2021-03-19 Impact factor: 19.103
Authors: Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber Journal: N Engl J Med Date: 2020-12-10 Impact factor: 91.245
Authors: Sara E Oliver; Julia W Gargano; Mona Marin; Megan Wallace; Kathryn G Curran; Mary Chamberland; Nancy McClung; Doug Campos-Outcalt; Rebecca L Morgan; Sarah Mbaeyi; José R Romero; H Keipp Talbot; Grace M Lee; Beth P Bell; Kathleen Dooling Journal: MMWR Morb Mortal Wkly Rep Date: 2021-01-01 Impact factor: 35.301
Authors: Rebecca B Blank; Rebecca H Haberman; Kun Qian; Marie Samanovic; Rochelle Castillo; Anthony Jimenez Hernandez; Parvathy Vasudevapillai Girija; Sydney Catron; Zakwan Uddin; Paula Rackoff; Gary Solomon; Natalie Azar; Pamela Rosenthal; Peter Izmirly; Jonathan Samuels; Brian Golden; Soumya Reddy; Mark J Mulligan; Jiyuan Hu; Jose U Scher Journal: Rheumatology (Oxford) Date: 2022-05-28 Impact factor: 7.046
Authors: Lisa G Rider; Christine G Parks; Jesse Wilkerson; Adam I Schiffenbauer; Richard K Kwok; Payam Noroozi Farhadi; Sarvar Nazir; Rebecca Ritter; Emily Sirotich; Kevin Kennedy; Maggie J Larche; Mitchell Levine; Sebastian E Sattui; Jean W Liew; Carly O Harrison; Tarin T Moni; Aubrey K Miller; Michael Putman; Jonathan Hausmann; Julia F Simard; Jeffrey A Sparks; Frederick W Miller Journal: Rheumatology (Oxford) Date: 2022-06-28 Impact factor: 7.046
Authors: Michele Maria Luchetti Gentiloni; Valentino Paci; Valentina Marconi; Marco Gigli; Devis Benfaremo; Raffaella Sordillo; Cristina Macchini; Leonardo Massaccesi; Gian Piero Perna; Anna Maria Offidani; Gianluca Moroncini Journal: Front Immunol Date: 2022-03-21 Impact factor: 7.561
Authors: Rebecca Grainger; Alfred H J Kim; Richard Conway; Jinoos Yazdany; Philip C Robinson Journal: Nat Rev Rheumatol Date: 2022-02-25 Impact factor: 32.286
Authors: Monica M Yang; Kimberly E Taylor; Diana Paez; Alex Carividi; Emanuel Demissie; Niti Pawar; Alia A El-Qunni; Lily E McMorrow; Rebecca E Schriefer; Katherine Huang; Baylee Kinnett; Michael Klebert; Alem Haile; Jane A O'Halloran; Rachel M Presti; Wooseob Kim; Ali H Ellebedy; Matthew A Ciorba; Michael A Paley; Parakkal Deepak; Alfred H J Kim; Patricia Katz; Mehrdad Matloubian; Mary Nakamura; Lianne S Gensler Journal: Arthritis Care Res (Hoboken) Date: 2022-04-12 Impact factor: 5.178